Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity, as well as MET-815i to reduce weight or prevents weight gain. The company was incorporated in 2022 and is based in New York, New York. Show more

Location: 3 World Trade Center, New York, NY, 10007, United States | Website: https://metsera.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

4.127B

52 Wk Range

$12.30 - $40.47

Previous Close

$36.41

Open

$35.40

Volume

937,595

Day Range

$34.52 - $40.47

Enterprise Value

2.41B

Cash

588.3M

Avg Qtr Burn

-34.65M

Insider Ownership

13.07%

Institutional Own.

77.75%

Qtr Updated

03/31/25

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
MET-034i + MET-097i Details Overweight or obesity Suspected Mover™ Susp. Mover™	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
MET-233i Details Overweight or obesity Suspected Mover™ Susp. Mover™	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
MET-233i + MET-097i Details Overweight or obesity Suspected Mover™ Susp. Mover™	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.